Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer
Author:
Affiliation:
1. Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicine and Early Development; AstraZeneca; Waltham MA USA
2. qPharmetra; LLC; Stockholm Sweden
Funder
AstraZeneca
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13495/fullpdf
Reference32 articles.
1. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J Clin Oncol,2012
2. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer;Lieu;PLoS One,2013
3. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family;Brave;Mol Cancer Ther,2011
4. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms;Decio;Am J Pathol,2014
5. Cediranib affects tumor progression and survival of mice bearing patient derived ovarian carcinoma xenografts (EOC-PDX);Decio;Cancer Res,2014
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status;Journal of Hematology & Oncology;2021-11-06
2. Optimal designs for regional bridging studies using the Bayesian power prior method;Pharmaceutical Statistics;2019-08-25
3. An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy;Expert Opinion on Drug Safety;2019-05-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3